Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2015-03-31
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bioequivalence Study of Idalopirdine in Healthy Subjects
NCT02894515
Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fasting Condition
NCT01735370
Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fed Condition
NCT01627847
Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fed Condition
NCT01831687
Pharmacokinetics of Two Eletriptan Oral Formulations Given With and Without Water and the Commercial Tablet Formulation Given With Water
NCT00871806
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Idalopirdine 60 mg formulation A (test)
Idalopirdine 60 mg formulation A (test)
Tablet for oral use, single dose
Idalopirdine 60 mg formulation B (reference)
Idalopirdine 60 mg formulation B (reference)
Tablet for oral use, single dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Idalopirdine 60 mg formulation A (test)
Tablet for oral use, single dose
Idalopirdine 60 mg formulation B (reference)
Tablet for oral use, single dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
-≥18 and ≤55 years of age
* body mass index (BMI) of \>18.5 and \<30 kg/m2
Exclusion Criteria
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
H. Lundbeck A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Covance
Leeds, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-001799-69
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
16052A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.